Overview
Onconick develops antibody-drug conjugates (ADCs) for precision treatment of challenging cancer types, targeting novel, highly specific markers. The company develops methods for molecular target selection and antibody characterization and uses its in-house platform for recombinant protein engineering and ADC development.
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 74 days late).
- 202507/07/2026
- 202410/07/2025
- 202327/06/2024
- 202230/06/2023
- 202127/09/2022
- 202030/06/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Offer
- Cancer therapies
- ADC drugs
- Oncology research
- Protein engineering
- Antibody characterization
- Drug development
Authorized Representatives
Manner of representation
If more than one person is appointed to the management board, the company shall be represented by two members of the management board acting jointly.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 60 | $810.37 | 17.0455% | |
Daniel Rafał Krowarschage 55 | 81 | $1,094.00 | 23.0114% |
Jacek Józef Otlewskiage 70 | 29 | $391.68 | 8.2386% |
| 81 | $1,094.00 | 23.0114% | |
Małgorzata Urszula Zakrzewskaage 49 | 81 | $1,094.00 | 23.0114% |
Others | 20 | $270.12 | 5.6817% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-05-01.
83 1240 1037 1111 0011 4188 9882- 17 1240 1037 1111 0011 4188 9518
07 1140 2004 0000 3702 7966 6123
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Oct 8, 2025 | Commercial Companies Code notice |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 31, 2022 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Jan 23, 2020 | Aid for SME access to finance — aid for start-ups | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| AI Corelabsp. z o.o. | $106,857.00 | aicorelab.com | ||
| Oncocdxsp. z o.o. | $58,823.32 | oncocdx.org | ||
| Receptonsp. z o.o. | $50,611.05 | receptonbiotech.com | ||
| Biostat Research and Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| Orphinic ScientificS.A. | $42,972.42 | orphinic.com | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| CannamedaiS.A. | $28,203.90 | cannamedai.com | ||
| Pioligonsp. z o.o. | $29,597.16 | pioligon.pl | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-11-22 | Share capital increase (7,850.00 PLN → 17,600.00 PLN) | |
| 2021-03-12 | Share capital increase (5,000.00 PLN → 7,850.00 PLN) | |
| 2020-01-21 | Entered in the register |
FAQ
Last updated: 2026-10-03